L-leucine in Diamond Blackfan Anemia Patients

Diamond Blackfan Anemia Clinical Trial

Official title:

Therapeutic Use of the Amino Acid Leucine in the Treatment of Transfusion-Dependent Diamond Blackfan Anemia Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02386267
• Other study ID #: Ru0001
• Status: Recruiting
• Phase: Phase 2
• First received: February 18, 2015
• Last updated: March 5, 2015
• Start date: September 2014
• Est. completion date: March 2016

Study information

• Verified date: March 2015
• Source: Federal Scientific Clinical Centre of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogache
• Contact: Natalia - SMETANINA, MD, PhD
• Phone: +7 985 647 13 05
• Email: Nataliya.Smetanina[@]fccho-moscow.ru
• Is FDA regulated: No
• Health authority: Russia: Ministry of Health of the Russian Federation
• Study type: Interventional

Clinical Trial Summary

Diamond-Blackfan anemia (DBA) is a rare congenital syndrome associated with physical anomalies, short stature, red cell aplasia, and an increased risk of malignancy.

Mutations affecting genes encoding ribosomal proteins cause DBA. Genetic studies have identified heterozygous mutations in at least one of eight ribosomal protein genes in up to 50% of cases.

25% of patients carry a mutation in the ribosomal protein (RP)S19 gene, whereas mutations in RPS24, RPS17, RPL35A, RPL11, and RPL5 are rare.

p53 activation has been identified as a key component in the pathophysiology of DBA after cellular and molecular studies. Other potential mechanisms that warrant further investigation include impaired translation as the result of ribosomal insufficiency, which may be ameliorated by Leucine supplementation.

Despite significant improvements in understanding of the pathophysiology of Diamond Blackfan anemia (DBA), there have been few advances in therapy. The cornerstones of treatment remain corticosteroids,chronic red blood cell transfusions, and hematopoietic stem cell transplantation, each of which is fraught with complications. Other treatments have been shown to be effective in only a few patients or in individual case reports : IL-3, cyclosporine (alone or in combination with steroids), metaclopramide. Gene therapy is still a part of research programs.

There are some indications that the Amino Acid (AA) L-leucine, a translation enhancer, may have some efficacy in DBA and 5q-syndrome, which has the same altered ribosome functions as the DBA. L-leucine is an essential AA that is unique among the branched-chain AA acting as a nutrient regulator of protein synthesis in skeletal muscle and adipose tissue.

Several preclinical studies with DBA lymphocytes exposed to various L-leucine doses, have demonstrated that protein synthesis can be increased by using high doses L-leucine.

Recent clinical data on L-leucine therapeutic use have demonstrated increase the hemoglobin level and transfusion independence in patients with DBA and 5q-syndrom.

These data support the rationale for clinical trial on L-leucine use as a therapeutic agent for DBA patients.

Description:

Experimental: one arm L-leucine , dose- 700mg/m2 , per os, 3 time a day, 6 months

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: March 2016
• Est. primary completion date: March 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 1 Year to 20 Years

Eligibility

Inclusion Criteria:

• signed Informed Consent Form

• diagnosed Diamond Blackfan Anemia

• transfusion dependen?e

• adequate renal function

• adequate liver function

• negative B-HCG and adequate contraception

Exclusion Criteria:

• known hypersensitivity to branched chain amino acids

• diagnosed AA metabolism disorder

• prior HSCT

• pregnancy or planning to become pregnant

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Anemia
• Anemia, Diamond-Blackfan
• Diamond Blackfan Anemia

Intervention

Drug:
• L-leucine
L-leucine pills per os for 6 months

Locations

Country	Name	City	State
Russian Federation	Federal Scientific Clinical Centre of Pediatric Hematology Oncology Immunology n.a. Dmitry Rogachev	Moscow

Sponsors (1)

Lead Sponsor	Collaborator
Federal Scientific Clinical Centre of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogache

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hemoglobin level	Response to the treatment can be one of the following: Complete response (CR): Hb > 9 gm/dL and transfusion-independence as defined in DBA; Partial response (PR): Hb < 9 gm/dL, increased reticulocyte count > 1% and any increase in transfusion interval from baseline.; No response (NR): no change in transfusion requirements and no significant change in Hb or reticulocytes; Progression: worsening of disease as defined by the need for more frequent transfusions	every 4 weeks for 12 months	No
Secondary	Side effects of L-leucine in transfusion-dependent DBA patients for one year		every 4 weeks for 12 moths	Yes